| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 62.3 | 113.7 |
| Gross profit | 49.7 | 95.0 |
| Profit before tax | -11.1 | 22.8 |
| Net income | -8.7 | 16.7 |
| EPS (diluted, $ a share) | $-0.06 | $0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -45.2% |
|---|---|
| Gross margin | 79.8% |
| Operating margin | -18.8% |
10-Q filed with the SEC, NASDAQ: MDXG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mimedx Group, Inc.: key numbers
- Share price
- $3.18Close, Nov 16
- Market cap
- $464M
- Shares outstanding
- 145.93MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mimedx Group, Inc.
All →Mimedx Group Financial Results
MiMedx Group reported Q3 2026 financial results, highlighting a 45% year-over-year revenue decline to $62 million primarily due to Medicare reimbursement changes affecting its Wound business. Despite the overall decline, the Surgical franchise grew 9% and the company returned to positive Adjusted EBITDA following cost-reduction initiatives.
“Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.”
Joseph H. Capper, MIMEDX Chief Executive Officer
“We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech. As we prepare for the combination of the two companies, our conviction in both the strategic rationale and the financial merits of this transaction remains strong,”
Joseph H. Capper, MIMEDX Chief Executive Officer
Mimedx Group M&A Deal with Sanara MedTech Inc.
MiMedx Group and Sanara MedTech each received a 'Second Request' for information from the FTC regarding their pending merger. This action extends the HSR Act waiting period until 30 days after both parties substantially comply with the request, unless terminated earlier by the regulator.
- Counterparty
- Sanara MedTech Inc.